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Small Ubiquitin-like Modifier (SUMO) is a ∼10 kDa peptide that can be post-
translationally added to a lysine (K) on a target protein to facilitate protein–protein
interactions. Recent studies have found that SUMOylation can be regulated in an
activity-dependent manner and that ion channel SUMOylation can alter the biophysical
properties and surface expression of the channel. Hyperpolarization-activated cyclic
nucleotide-gated (HCN) channel surface expression can be regulated in an activity-
dependent manner through unknown processes. We hypothesized that SUMOylation
might influence the surface expression of HCN2 channels. In this manuscript, we
show that HCN2 channels are SUMOylated in the mouse brain. Baseline levels of
SUMOylation were also observed for a GFP-tagged HCN2 channel stably expressed
in Human embryonic kidney (Hek) cells. Elevating GFP-HCN2 channel SUMOylation
above baseline in Hek cells led to an increase in surface expression that augmented
the hyperpolarization-activated current (Ih) mediated by these channels. Increased
SUMOylation did not alter Ih voltage-dependence or kinetics of activation. There are
five predicted intracellular SUMOylation sites on HCN2. Site-directed mutagenesis
indicated that more than one K on the GFP-HCN2 channel was SUMOylated. Enhancing
SUMOylation at one of the five predicted sites, K669, led to the increase in surface
expression and Ih Gmax. The role of SUMOylation at additional sites is currently
unknown. The SUMOylation site at K669 is also conserved in HCN1 channels. Aberrant
SUMOylation has been linked to neurological diseases that also display alterations in
HCN1 and HCN2 channel expression, such as seizures and Parkinson’s disease. This
work is the first report that HCN channels can be SUMOylated and that this can regulate
surface expression and Ih.
Keywords: SUMO, HCN, trafficking, ion channel, hyperpolarization-activated cyclic nucleotide-gated channel,
cyclic nucleotide binding domain
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INTRODUCTION
Post-translational modifications can rapidly regulate proteins.
SUMOylation is one such modification that is essential for
most organisms (Flotho and Melchior, 2013). Small Ubiquitin-
like Modifier (SUMO, a.k.a. Sentrin) is a ∼100 amino acid
peptide that is covalently added to a lysine (K) residue on a
target protein. The addition involves several steps. First, the
immature SUMO protein is cleaved by a sentrin specific protease
(SENP), exposing a C-terminal diglycine (Mukhopadhyay and
Dasso, 2007). The SUMO E1 activating enzyme then transfers
the mature SUMO peptide to the E2 conjugating enzyme, Ubc9,
which will then add SUMO to the target protein (Desterro
et al., 1997). SUMO can also be deconjugated from a target
protein by SENP (Hickey et al., 2012). In mammals, SUMO
is encoded by a family of four genes, termed SUMO1–4
(Flotho and Melchior, 2013). SUMO2 and SUMO3 proteins
are ∼97% identical and are not readily distinguishable in
most experiments. SUMO1 and SUMO2/3 proteins share ∼46%
identity, and their sets of targets greatly overlap. SUMO4 cannot
be cleaved into the mature form by SENP, and its function is
unclear.
Modification by SUMO is subject to numerous forms of
regulation. The availability of the SUMOylation site on a
target protein can be regulated by the presence of other
post-translational modifications. For example, phosphorylation
near the SUMOylation site can either inhibit or enhance
SUMOylation (Bossis and Melchior, 2006; Konopacki et al.,
2011). SUMOylation can also be regulated by the availability of
SUMO and/or SUMOylation enzymes (Loriol et al., 2013).
SUMOylation mediates protein–protein interactions
(Makhnevych et al., 2009; Flotho and Melchior, 2013). As
such, SUMO can coordinately regulate many diverse cellular
processes ranging from DNA repair in the nucleus to signal
transduction at the plasma membrane (Hickey et al., 2012). The
effects of SUMO are observed throughout the neuron (Henley
et al., 2014). SUMOylation can influence neuronal transcription
by controlling the stability of transcription factors; for example,
BMAL1 ubiquitination and degradation is enhanced when
it is SUMOylated (Lee et al., 2008). SUMO can also regulate
synaptic release. SUMOylation of the synaptic vesicle protein,
RIM1α, promotes its direct interaction with Cav2.1 channels,
causing them to form clusters, which leads to rapid exocytosis of
synaptic vesicles (Girach et al., 2013). In addition, SUMOylation
plays a role in the trafficking of integral membrane proteins
such as kainate receptors. SUMOylation of GluK2 is required
for agonist-induced internalization of the kainate receptor,
likely by facilitating its interaction with scaffolding and/or
trafficking proteins (Konopacki et al., 2011; Chamberlain et al.,
2012). However, the distinct interaction that leads to GluK2
internalization is still unknown. Voltage-gated ion channels
are fundamental constituents of the neuronal membrane. Their
trafficking is complex and highly regulated. The functions of
SUMOylation in voltage-gated ion channel trafficking are largely
unknown. We are interested in the role of SUMOylation in
the regulated trafficking of hyperpolarization-activated cyclic
nucleotide gated (HCN) ion channels.
HCN channels play a pivotal role in shaping neuronal
excitability and synaptic integration by influencing several
neuronal activity features including membrane potential, firing
threshold, resonance frequency, temporal summation, and
synaptic strength (Hutcheon and Yarom, 2000; Wahl-Schott
and Biel, 2009; Shah, 2014). The mammalian HCN1–4 gene
family encodes distinct channel isoforms (He et al., 2014).
All isoforms are permeable to K+ and Na+, activate upon
hyperpolarization, and mediate a slowly depolarizing current
termed the hyperpolarization-activated current (Ih). Besides
being activated at hyperpolarized potentials, HCN channels
can also be gated by the binding of cyclic nucleotides to the
C-terminal cyclic nucleotide binding domain (CNBD) found
in all isoforms (Robinson and Siegelbaum, 2003; He et al.,
2014).
HCN channel isoforms differ in their biophysical properties
and modulation by cAMP. Under basal conditions, the CNBD
inhibits hyperpolarization-gating to a different extent in each
isoform due to its isoform-specific interactions with the core
transmembrane domain and the C-linker that connects the
CNBD to the transmembrane domain (Wang et al., 2001).
This variable inhibition results in isoform-specific steady-state
activation curves. For example, the steady-state activation
curve of HCN2 channels is 20 mV more hyperpolarized
compared with HCN1 channels. Binding of cAMP to the CNBD
relieves its inhibition on hyperpolarization-gating. Because
of the isoform-specific interactions between the CNBD and
the C-linker, the effect of cAMP binding will vary with
the isoform (Wang et al., 2001). For example, binding of
cAMP to the CNBD of HCN2 and HCN1 channels shifts
their respective activation curves to more positive potentials,
but HCN2 channels display a 17 mV shift while HCN1
channels display a 4 mV shift. Maximal effects of cAMP
binding are observed for HCN2 and HCN4 isoforms. The
activation kinetics also varies between isoforms with HCN1
and HCN4 having the fastest and slowest activation kinetics,
respectively.
In addition to their distinct biophysical properties and
cAMP modulation, each of the four isoforms also displays
a unique expression pattern in the nervous system (He
et al., 2014). HCN1 is highly enriched in the neocortex,
hippocampus, cerebellar cortex, and brainstem. HCN2 is
widely expressed in most brain regions, while HCN3 has low
expression levels in the nervous system. HCN4 expression
mirrors HCN1 and is also selectively expressed in several
thalamic nuclei and neuronal populations in the basal ganglia
and habenular cortex. The formation of heteromeric channels
further enhances the complexity of Ih function and modulation
in vivo.
HCN channel surface expression throughout the nervous
system can be adjusted over several time courses (Zha et al.,
2008; Shah, 2014; Furst and D’Avanzo, 2015; Smith et al.,
2015; Brennan et al., 2016). Regulated SUMOylation could
play a role in the trafficking of HCN channels. Since the
trafficking of HCN2 channels has been fairly well studied
(see Discussion), here we examine SUMOylation of HCN2
channels.
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MATERIALS AND METHODS
Drugs
All drugs were obtained from Sigma-Aldrich with the exception
of Tween 20 (Fisher Scientific).
Mouse Brain Membrane Preparations
Non-denaturing
A single mouse forebrain was homogenized on ice in
homogenization buffer (5 mM NaH2PO4 buffer, 0.32 M
sucrose) supplemented with protease inhibitor cocktail (1:100,
Sigma cat. #P8340) and 20 mM N-Ethylmaleimide (NEM)
to prevent SUMO deconjugation (Suzuki et al., 1999). Cell
debris was pelleted at 5,000 rpm for 10 min at 4◦C, and the
supernatant was retained and further centrifuged at 40,000 rpm
for 90 min at 4◦C to pellet membrane-bound proteins. The
supernatant was removed and the pellet containing intracellular
and extracellular membrane bound proteins was resuspended in
1 ml of resuspension buffer (0.5% SDS, 5 nM NaH2PO4, protease
inhibitor cocktail at 1:100) followed by shaking at 4◦C for 1 h.
Denaturing
Tissue homogenization and centrifugation were the same as
for the non-denaturing preparation. The membrane pellet was
resuspended in 100µl of denaturing buffer (2% SDS, 50 mM Tris-
HCl pH7.5, 5 mM DTT) followed by shaking at 4◦C for 1 h. The
preparation was then diluted to 1 ml total volume with dH2O
and boiled for 10 min. In all cases, protein concentration was
determined with a bicinchoninic acid assay (BCA Assay, Pierce
BCA Protein Assay Kit). Mouse brain membrane fractions were
obtained from whole mouse forebrain tissue generously provided
by Dr. Chun Jiang. All animal procedures were conducted in
compliance with the regulation of the Institutional Animal Care
and Use Committee of Georgia State University.
Plasmids and Antibodies
A previously described mouse GFP-HCN2 fusion plasmid
(Santoro et al., 2004) was generously provided by Dr. Bina
Santoro’s Lab. Plasmids for transient transfection include the
following: mCherry2-C1 was a gift from Michael Davidson
(Addgene plasmid # 54563), Ubc9 (Yasugi and Howley, 1996)
was a gift from Peter Howley (Addgene plasmid # 14438), SENP1
(Cheng et al., 2007) was a gift from Edward Yeh (Addgene
plasmid # 17357), and SUMO2 (Kamitani et al., 1998) was a gift
from Edward Yeh (Addgene plasmid # 17360). Antibodies used
are shown in Table 1, and the specificity of each antibody was
verified as indicated in the table.
Site-Directed Mutagenesis
PCR was used to create two site-directed mutations in the
GFP-HCN2 fusion plasmid described above: K534R and K669R.
The two sets of primers are listed in Table 2. PrimeStar GXL
polymerase (Takara) was used along with the buffer, nucleotides,
and instructions supplied by the manufacturer. Typically, 10 ng
of plasmid DNA served as the template in a 50 µl reaction.
The cycling conditions were: 1x 98◦C, 1 min; 30x 98◦C, 30 s,
68◦C, 7 min; 1x 68◦C, 5 min. Upon completion, 20 units of
DpnI (Clontech) were added to the reaction, which was incubated
at 37◦C for 1–2 h to digest the template DNA. Afterward, 1–
2 µl of the reaction was added to a 50 µl aliquot of subcloning
grade competent XL1blue cells (Agilent) and incubated on ice
for 30 min. The cells were then heat-shocked at 42◦C for 45 s.
NZY broth (100 µl) was added, and the cells were incubated at
37◦C for 20 min to allow for expression of kanamycin resistance.
Cells were then plated on NZY plates containing 30 µg/ml
kanamycin and incubated at 37◦C overnight. Plasmid DNA from
resultant colonies was isolated (Qiagen), the insert was sequenced
in its entirety, and analyzed with Lasergene software (DNAstar)
to ensure that only the intended mutation was generated. All
sequencing was done by the Georgia State University Cell
Protein and DNA Core Facilities. To create multiple mutations,
a previously mutated GFP-HCN2 fusion plasmid was used as the
template for a PCR with a different primer.
Cell Culture, Stable, and Transient
Transfections
Hek-293 cells and all cell culture reagents were obtained from
American Type Culture Collection (ATCC; Manassas, VA, USA).
Hek-293 cells were cultured at 37◦C, and 5% CO2 in EMEM
media supplemented with 10% fetal bovine serum and 1%
Penicillin-Streptomycin.
Transfections to Produce Stable Lines
A cell line stably expressing a GFP-HCN2 fusion protein (Hek-
HCN2) was generated by transfecting a 60 mm plate of Hek-
293 cells with the GFP-HCN2 plasmid using Lipofectamine
2000 (Invitrogen) according to instructions provided by the
manufacturer. After 2 days, transfected cells were trypsinized,
resuspended, and replated to 60 mm plates (5–20 µl of a 1 ml
cell resuspension per 60 mm plate) and the selection agent, G418
(Geneticin, Gibco, 500 µg/ml), was added to the media. After 3–
5 weeks, individual colonies were selected using cloning rings.
Stable expression was checked by fluorescence and whole cell
patch clamping for Ih. In all cases, a colony was selected only if
GFP and Ih was observed in every cell; however, the intensity of
GFP expression and Ih maximal conductance could vary between
colonies from the same transfection by a factor of 10, presumably
due to differences in the number of copies of plasmid integrated
into the host cell genome. Stable cell lines expressing mutant
versions of GFP-HCN2 were generated in a similar fashion.
Transient Transfections
In our hands, Lipofectamine transfection efficiencies ranged
from 5 to 25%. This was not adequate for transient transfection
experiments, which required 80–100% transfection efficiency.
Therefore, a high efficiency calcium phosphate transfection
was employed for immunoprecipitation (IP), biotinylation and
patch clamping experiments using transient transfection to
increase or decrease SUMOylation. Briefly, cells were plated
at ∼60% confluence on 100 or 60 mm cell culture dishes
24 h before transfection. The media was changed at least 1 h
before transfection. For a single 100 or 60 mm dish, 25 or
10 µg of total plasmid DNA was diluted in 440 or 250 µl of
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TABLE 1 | Primary antibodies.
Antigen Verification of specificity Manufacturer, species, cat no. Concentration used
SUMO2/3 Specificity verified by company through Western blot (WB) analysis of
Hek-293 cells transfected with SUMO2
Santa Cruz Biotechnology, rabbit
polyclonal, cat. no. sc-32873
WB: 1:3000
SUMO1 Specificity verified by company through WB analysis of Hek-293 with
and without SUMO1 expressed
Santa Cruz Biotechnology, rabbit
polyclonal, sc-9060
WB: 1:3000
GFP (for WB) Specificity verified by company through WB analysis of cells with and
without GFP expressed
Santa Cruz Biotechnology, rabbit
polyclonal, cat. no. sc-8334
WB: 1:4000
GFP (for IP) We verified specificity through WB analysis (Figure 2) Abcam, rabbit polyclonal, cat. no.
ab290
1 µl per 500 µg of lysate
HCN2 Specificity verified by company through WB analysis of cells with and
without HCN2 expressed
Santa Cruz Biotechnology, goat
polyclonal, sc-19708
WB: 1:3000 (Hek cells)
HCN2 Specificity verified by company through WB analysis of mouse and rat
membrane proteins
UC Davis/NIH NeuroMab, mouse
monoclonal, N71/37
WB 1:200 (Mouse brain)
Actin Specificity verified by company through WB analysis of non-transfected
and β-Actin transfected Hek-293 cells




Na+/K+-ATPase Specificity verified by company through WB analysis of Human, Mouse
and Rat tissues expressing the Na+/K+-ATPase
Abcam, mouse monoclonal, cat.
no. ab7671
WB: 1:3000
TABLE 2 | Site directed mutagenesis primers.









TE buffer (10 mM Tris-HCl pH8, 1 mM EDTA), respectively.
Then, 60 or 30 µl of 2 M CaCl2 was added dropwise to the
DNA followed by the addition of 500 or 250 µl of 2× HBS
(275 mM NaCl, 10 mM KCl, 12 mM Dextrose, 1.4 mM Na2HPO4,
40 mM HEPES, pH 7.1), respectively. Calcium Phosphate/DNA
precipitate was then immediately dropped onto cells. Cells were
returned to 37◦C and 5% CO2 for 4 h followed by either a
media change or passaging to 20 mm Poly-L-Lysine coated
coverslips and allowed to grow another 24–48 h. Cells were
transfected with plasmid DNA expressing either mCherry or a
mixture of mCherry + SUMO + Ubc9 or mCherry + SENP1.
For co-transfection of multiple plasmids, the total amount of
plasmid DNA remained the same (25 or 10 µg) but comprised
equal amounts of each of the different plasmids (1:1:1 or 1:1).
Transfection efficiency was determined to be the percentage of
cells expressing mCherry as judged by fluorescence microscopy.
The transfection efficiency of every plate was checked for each
experiment, and a plate was only used if the transfection efficiency
exceeded 80%.
Immunoprecipitations
GFP-HCN2 IP from Hek Cells
One hundred millimeter plates containing Hek cells were washed
twice with ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4, pH 7.4) followed by the addition
of RIPA buffer (1% NP40, 50 mM Tris pH 7.4, 150 mM NaCl,
0.1% SDS, 0.5% DOC, 20 mM EDTA, protease inhibitor cocktail
at 1:100 and 20 mM NEM) to the plate. Cells were lysed on the
plate for 30 min on ice, rocking occasionally. A disposable cell
scraper was used to scrape any remaining cell debris from the
bottom of the plate, and the lysate was collected and transferred
to a sterile tube. Cell debris was pelleted at 12,000 rpm for 10 min
at 4◦C, and the supernatant was retained. Protein concentration
was determined with a BCA assay. IPs were performed using the
Classic Magnetic Co-IP Kit (Pierce), following the manufacturer’s
instructions. Typically 1 mg of protein was added to the beads and
the protein was eluted from the beads in a volume of 100 µl.
HCN2 IP from Mouse Forebrain
1.5 mg of the mouse membrane preparation with 5 µg of anti-
HCN2 antibody (Table 1, Santa Cruz Biotechnology; sc-19708)
were used in combination with the Classic Magnetic Co-IP Kit
(Pierce), following the manufacturer’s instructions. Protein was
eluted from the beads in a volume of 100 µl and 20 µl was used
for one lane of an SDS-PAGE gel.
Western Blotting
Protein samples were run on an SDS-PAGE gel and transferred
to a PDVF membrane using a semidry electroblotting system.
A membrane was blocked for 1 h in a solution of 5% non-fat
powdered milk in TBS (10 mM Tris-HCl pH7.5, 150 mM NaCl),
washed for 10 min in TTBS (1x TBS, 0.1% Tween 20), and then
incubated overnight at 4◦C with the primary antibody, diluted
as described in Table 1, in 1% non-fat powdered milk in TTBS.
The membrane was then washed 3x 5 min each in TTBS and then
incubated with the appropriate alkaline phosphatase conjugated
secondary antibody, diluted in 1% non-fat powdered milk in
TTBS for 2 h at room temperature. Following incubation with the
secondary antibody, the membrane was washed 3x 10 min each
and Immunstar AP substrate (BioRad) was added to the surface
of the membrane, incubated 5 min and then exposed to X-ray film
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to detect chemiluminescent signals. In some cases, membranes
were stripped and reprobed. Stripping involved washing the blot
2x 5 min each in mild stripping buffer [200 mM Glycine, 0.1%
SDS, 1% (v/v) Tween 20, pH 2.2]. The blot was then washed 2x
10 min each in PBS and 2x 5 min each in TTBS. The blot was
then exposed to film to ensure the signal was removed.
Patch Clamping Electrophysiology
Coverslips (20 mm) were dipped in ethanol, allowed to air dry,
and incubated with Poly-L-Lysine (50 µg/ml in dH2O) at 37◦C
for 1 h. Coverslips were then washed once with sterile dH2O,
air dried, and stored at 4◦C. For an experiment, coverslips were
seeded with 8 × 104 cells, and the next day coverslips containing
transiently transfected cells were placed into a chamber and
constantly perfused with extracellular saline solution (138 mM
NaCl, 5.6 mM KCl, 2.6 mM CaCl2, 1.2 mM MgCl2, 10 mM
HEPES, 10 mM Glucose, pH 7.4). Cells were visualized on an
Olympus IX70 microscope and transiently transfected cells were
identified by fluorescence and only those expressing mCherry
were used for whole cell patch clamping experiments. A fire-
polished micropipette (Sutter Instruments, 6–8 M) was filled
with intracellular solution (10 mM NaCl, 145 mM KCl, 1 mM
MgCl2, 5 mM HEPES, pH 7.2) and connected to an Axopatch
200B amplifier (Molecular Devices, Foster City, CA, USA).
To obtain a whole cell patch, a gentle negative pressure was
used to form a ≥1 G seal between the cell membrane and
the opening of the micropipette. Suction was used to rupture
the cell membrane and recordings were taken from cells that
maintained a seal ≥700 M following rupture. Cells were held
at −50 mV using pClamp 10 software and Ih was elicited using
5 s hyperpolarizing voltage steps from −50 to −120 mV in
10 mV increments with 4 s between each step. Steady-state peak
current was measured by subtracting the initial fast leak current
from the slowly activating Ih for each hyperpolarizing voltage
step. Conductance was calculated using the peak current at each
voltage step (G= Ipeak/(Vm−Vrev); Vrev Ih =−35 mV) and fitted
to a first order Boltzmann equation.
Cell Surface Biotinylation
Hek-HCN2 cells plated on 60 mm culture dishes were
transiently transfected with either mCherry alone (control) or
mCherry + SUMO + Ubc9. Cells were washed twice with
ice-cold PBS, supplemented with 0.2 mM CaCl2 and 1.5 mM
MgCl2 (PBS-CM) and incubated for 30 min at 4◦C with 2 ml
of 0.5–1 mg/ml of EZ-link Sulfo-NHS-SS-Biotin (Thermo Fisher,
cat#21331). Cells were washed twice with ice cold PBS-CM, and
residual biotin was quenched with PBS-CM plus 100 mM glycine
for 15 min at 4◦C. Cells were washed once more with PBS-
CM followed by lysis with 500 µl of ice cold RIPA buffer (1%
NP40, 50 mM Tris pH 7.4, 150 mM NaCl, 0.1% SDS, 0.5%
DOC, 2 mM EDTA, protease inhibitor cocktail at 1:100) for
30 min on ice. A disposable cell scraper was used to remove
any residual cell debris from the bottom of the plate, and the
contents were transferred to a microcentrifuge tube. Cell debris
was pelleted by centrifugation at 12,000 rpm for 10 min. The
supernatant was removed and immediately incubated for 2 h
at 4◦C with 100 µl of Neutravidin agarose resin (Pierce, cat
#29201) with agitation. The lysate/resin mixture was centrifuged
in a spin column (Thermo Fisher, cat #69725) at 1,000 × g for
2 min. The flow through containing unbiotinylated intracellular
proteins was retained for Western blot (WB) analysis. The resin
was washed three times in PBS supplemented with 1% NP40,
and 0.1% SDS and three times in PBS supplemented with 0.1%
NP40 and 0.5 M NaCl, centrifuging at 500× g for 1 min between
each wash. Columns were capped, and biotinylated proteins were
eluted from the beads by incubating for 1 h at room temperature
with 50 µl of SDS loading buffer (50 mM Tris-HCL pH 6.8,
100 mM DTT, 2% SDS, 0.1% Bromophenol blue, and 10%
glycerol). Columns were uncapped and centrifuged at 1,000 × g
for 2 min to collect the eluted extracellular proteins. Intracellular
and extracellular fractions were run on an SDS-PAGE gel and
transferred to a PVDF membrane. The membrane was cut at
∼50 kDa. The lower portion of the blot was probed with an anti-
actin antibody (Santa Cruz Biotechnology) to confirm that there
was no intracellular contamination in the extracellular samples.
The top portion of the blot was dually probed with an anti-GFP
antibody to detect the GFP-HCN2 channel, and an anti-Na+/K+-
ATPase antibody to use for normalization (Table 1). To confirm
that expression of the Na+/K+-ATPase was not varying across
treatment groups, samples from control and SUMO+Ubc9
transfected cells were run on a WB. The blot was stained
for total protein (SYPRO Ruby blot stain, Bio-Rad) and then
probed for the Na+/K+-ATPase. The Na+/K+-ATPase signal was
normalized by the total protein in the lane. A comparison of
the normalized Na+/K+-ATPase signal across treatment groups
indicated that there were no significant differences between
control and SUMO+Ubc9 transfected groups (Student’s t-test,
p> 0.05, n= 5).
Image Analysis and Quantification
ImageJ was used to quantify signals from WBs. Optical density
(OD) was measured using the Gel Analysis feature of the ImageJ
software. Briefly, a rectangular box was drawn around the signal,
and ImageJ software was then used to generate a profile plot of the
relative intensity. A line was drawn to isolate the area under the
curve and set the baseline, thereby subtracting the background,
and the area under the curve was measured. In order to ensure
images were not saturated, a series of exposures ranging from
underexposed to overexposed was always obtained, and only
intermediate exposures were quantified. Quantifying the fraction
of SUMOylated GFP-HCN2 channels in Hek cells involved
measuring a SUMO signal (entire GFP-HCN2 doublet) followed
by stripping and reprobing the membrane to obtain a GFP signal
(entire GFP-HCN2 doublet). In order to ensure that differences
between treatment groups were not due to differences created by
stripping or variability in the length of SUMO relative to GFP film
exposure, a complete set of treatment groups was present on each
blot, and measures for each treatment group were obtained from
the same exposure/film. However, variability within a treatment
group could be due to stripping and/or relative lengths of
exposures. At best, these experiments are semi-quantitative and
the fraction of SUMOylated channels in these cell lines may be
over/under-reported with this method. Nevertheless, this method
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FIGURE 1 | Mouse HCN2 is SUMOylated in vivo. Mouse forebrain non-denatured (A) and denatured (B) membrane fractions were used in immunoprecipitation
(IP) experiments with an antibody against HCN2 or IgG (negative control). Western blots (WBs) containing the IP products were probed for HCN2, SUMO1, and
SUMO2/3. The experiment was repeated three times using the brains from three different mice. Representative WBs are shown from a single experiment. The red
dots indicate non-specific products pulled down in the IP. The single band at ∼120 kDa represents HCN2 channels. The asterisk indicates a non-covalently bound,
SUMOylated protein. The band at ∼50 kDa represents the IP antibody.
suffices for detecting significant differences between treatment
groups.
Statistical Analysis
All data were analyzed using Prism 7 (Graphpad Software Inc.).
Each data set was checked for normality and homogeneity of
variance. Data were then analyzed using parametric statistical
tests, including Student’s t-test and One-way ANOVAs. In all
cases, the significance threshold was set at p < 0.05. Values
that were greater than two standard deviations from the mean
were considered statistical outliers and were excluded from the
data set. ANOVA’s were followed by post hoc tests that either
compared all groups to each other (Tukey’s) or to the control
(Dunnett’s). Unless otherwise stated all values are presented as
the mean± SEM.
RESULTS
Mouse HCN2 Is SUMOylated In vivo
To determine if the mouse HCN2 channel was SUMOylated
in vivo, an antibody against HCN2 (Table 1) or IgG (negative
control) was used to IP the channel from mouse forebrain
membrane preparations that were or were not denatured,
followed by WB analyses using antibodies against HCN2,
SUMO1, and SUMO2/3. Note that our anti-SUMO2/3 antibody
does not discriminate between SUMO2 vs. SUMO3; therefore,
the post-translational modification is referred to as SUMO2/3.
Figure 1 illustrates that HCN2 channels were post-translationally
modified by both SUMO1 and SUMO2/3 in the mouse
forebrain. Two bands at ∼120 and 75 kDa were observed
in the experimental preparations but not in the negative
controls. The band at ∼120 kDa was previously identified
as the HCN2 channel in mouse membrane preparations
(Much et al., 2003). It was observed in blots probed with
anti-HCN2, anti-SUMO1, and anti-SUMO2/3 in both non-
denaturing and denaturing IP experiments, which suggests
both SUMO1 and SUMO2/3 are covalently attached to HCN2
channels in the mouse forebrain. The ∼75 kDa band was
detected by the anti-SUMO antibodies, but not by the anti-
HCN2 antibody, on the WBs containing IP experiments using
non-denatured membrane preparations. Since this ∼75 kDa
band was not observed for the denaturing IP experiments, it
most likely represents an unknown SUMOylated protein that
non-covalently associates with HCN2 channels in the mouse
forebrain.
GFP-HCN2 Channels Are SUMOylated in
a Heterologous Expression System
Previous work suggested that SUMOylation could be
manipulated in tissue culture systems. We therefore generated
a Hek-293 cell line stably expressing a GFP-HCN2 fusion
protein (Hek-HCN2) as described in “Materials and Methods.”
Note that GFP is at the N-terminus of the HCN channel. IP
experiments were performed on parental Hek and Hek-HCN2
cell lysates using an anti-GFP antibody followed by WB analyses
with anti-GFP or anti-HCN2 antibodies (Figure 2). Both the
anti-GFP and the anti-HCN2 antibodies detected the same two
bands between 150 and 250 kDa (Figure 2A). This doublet was
not observed in the parental Hek cell line (Figure 2B). Together
these data suggested that the doublet represented the GFP-HCN2
channel. Previous studies on HCN2 channels expressed in Hek
cells showed that the doublet represented two forms of the
HCN2 channel (Much et al., 2003; Akhavan et al., 2005; Nazzari
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FIGURE 2 | Establishing a culture system to investigate HCN2 channel
SUMOylation. Cell lysates from a Hek cell line stably expressing GFP-HCN2
channels (A) and the parental Hek cell line (B) were used in IP experiments
with an antibody against GFP. WBs containing the lysate (L) and IP products
(IP) were then probed with anti-HCN2 and anti-GFP antibodies. A doublet was
recognized by both antibodies in the stably transfected but not parental Hek
cell line, suggesting that the doublet represents GFP-HCN2 channels. The
band present at 50 kDa in the IP lanes corresponds to the heavy chain of the
anti-rabbit antibody used in the IP experiment. The anti-rabbit secondary
antibody used in the GFP WB produced a strong signal. The anti-goat
secondary antibody used in the HCN2 WB produced a much weaker signal.
et al., 2008). The slower migrating band contained a complex
N-glycosylation. The faster migrating band instead possessed a
simple or no glycosylation. Complex N-glycosylation increased
the efficiency of surface expression, but channels possessing only
a subset of complex N-glycosylated subunits (Akhavan et al.,
2005) or no complex N-glycosylated subunits (Nazzari et al.,
2008) could still be detected at the plasma membrane. Relative
to past studies, the doublet detected in our experiments is larger,
presumably due to the GFP tag.
To determine if GFP-HCN2 channels were SUMOylated in
our culture system, we performed the same anti-GFP IP with
Hek-HCN2 cell lysates, followed by WB analyses using anti-
GFP (Figure 3, panel 1) and anti-SUMO2/3 (Figure 3, panel 2)
antibodies. The data indicated that both antibodies recognized
the same doublet between 150 and 250 kDa, suggesting that
GFP-HCN2 channels were SUMOylated in Hek-HCN2 cells (here
FIGURE 3 | GFP-HCN2 channels are SUMOylated in Hek-HCN2 cells.
Cell lysates from the Hek-HCN2 cell line were used in IP experiments with an
antibody against GFP. WBs containing the IP products were then probed with
an anti-GFP antibody or an anti-SUMO2/3 antibody. Parental Hek cell lysates
were also probed with the anti-SUMO2/3 antibody. The anti-SUMO2/3
antibody recognized the GFP-HCN2 doublet in the Hek-HCN2 cell line, but
not in the parental cell line, suggesting that GFP-HCN2 channels are
SUMOylated.
termed baseline SUMOylation). The SUMO signal was not due to
similarly sized endogenous Hek proteins associating with GFP-
HCN2 channels because the anti-SUMO2/3 antibody did not
detect the doublet on WBs containing parental Hek cell lysates
(Figure 3, panel 3).
Transient Transfection of SUMO2 and
Ubc9 Increases HCN2 Channel
SUMOylation in a Hek Cell Line Stably
Expressing Mouse HCN2
We next wished to manipulate GFP-HCN2 channel
SUMOylation in order to study its function. The conjugating
enzyme, Ubc9, adds SUMO to a target protein. In some cases,
Ubc9 is directed to a SUMOylation site by an external factor, such
as a SUMO interaction motif (SIM) domain or an E3 protein
(Flotho and Melchior, 2013). In other cases, Ubc9 directly
recognizes a consensus sequence and adds SUMO to the K in the
consensus sequence. Oftentimes the latter mechanism requires
additional stabilizing interactions provided by other proteins
or post-translational modifications; however, simply increasing
the concentration of the Ubc9 enzyme can obviate their need
at some (but not all) consensus sequences, and previous work
has demonstrated that SUMOylation of some target proteins can
be increased in cell culture by overexpressing SUMO and Ubc9
(Dai et al., 2009). Moreover, SENP has been shown to decrease
SUMOylation of some proteins in a heterologous expression
system (Dai et al., 2009; Dustrude et al., 2013) despite the fact that
SENP has opposing functions: endopeptidase activity removes
C-terminal amino acids to activate SUMO and promote target
protein SUMOylation; isopeptidase activity removes SUMO
conjugated to target proteins to promote deSUMOylation (Yeh,
2009).
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FIGURE 4 | Transient transfection with SUMO and Ubc9 leads to an
increase in GFP-HCN2 channel SUMOylation. The stable Hek-HCN2 cell
line was transiently transfected with mCherry (control), or
mCherry + SUMO + Ubc9, or mCherry + SENP1. Two days after
transfection, cell lysates were used in IP experiments with an anti-GFP
antibody. IP products were resolved with SDS-PAGE and transferred to WBs.
Blots were probed with an anti-SUMO2/3 antibody. After recording the result,
blots were stripped and reprobed with an anti-GFP antibody.
(A) Representative blots showing typical chemiluminescent signals for the
GFP-HCN2 channel doublet after probing with the anti-SUMO2/3 antibody
(upper panel) followed by stripping and re-probing with the anti-GFP antibody
(bottom panel). Note that the amount of IP product varied between
experiments but not across treatment groups as determined by measures of
the GFP OD’s [one-way ANOVA, F (2,16) = 0.1285; p = 0.8804]. (B) The
fraction of SUMOylated HCN2 channels in each treatment group (SUMO
doublet OD ÷ GFP doublet OD, see text) is plotted as the mean + SEM. The
treatment and the n are shown below each plot. Each n represents a single
plate that was transfected and carried through the experiment to produce a
single lane on a WB. Asterisk represents a statistically significant difference
from control [one-way ANOVA with a Dunnett’s post hoc, F (2,16) = 4.121;
p = 0.0360].
In order to investigate whether or not we could manipulate
SUMOylation of GFP-HCN2, the Hek-HCN2 cell line was
transiently transfected with plasmids expressing mCherry,
SUMO2, and Ubc9 or mCherry and SENP1. Control preparations
were transfected with mCherry alone. To determine the fraction
of HCN2 channels that were SUMOylated in each treatment
group, GFP-HCN2 channels were immunoprecipitated from
lysates using an anti-GFP antibody. WBs containing the IP
products were first probed with an anti-SUMO2/3 antibody.
Chemiluminescence was used to detect the SUMO signal, and
the OD for the entire GFP-HCN2 doublet was measured with
ImageJ (see Materials and Methods). After recording the SUMO
signal, the antibody was stripped, and the same blot was reprobed
with an anti-GFP antibody. Again, chemiluminescence was used
to detect the GFP signal, and the OD of the entire GFP-HCN2
doublet was measured. The fraction of SUMOylated channels
was defined as the OD of the SUMO signal divided by the
OD of the GFP signal (Figure 4A). This non-linear, semi-
quantitative method indicated that GFP-HCN2 SUMOylation
was significantly increased in the SUMO + Ubc9 group, by an
average of 50.7 ± 16.01% relative to the control (Figure 4B).
There was no significant difference in the amount of SUMOylated
channels in cells transfected with SENP1 relative to control. This
might suggest a low level of baseline HCN2 SUMOylation in the
Hek-HCN2 cell line. On the other hand, since SENP has two
opposing functions it is also possible that the balance of these two
functions does not change upon SENP1 overexpression, leaving
baseline SUMOylation unaltered. In sum, transient transfection
of SUMO and Ubc9 increases HCN2 SUMOylation in Hek-
HCN2 cells.
HCN2 Channel SUMOylation Increases Ih
Gmax
Hyperpolarization of Hek-HCN2 cells to −120 mV consistently
elicited an average peak Ih of 710 pA. This current was
never detected in the parental Hek cell line (n > 10);
thus, it is mediated by GFP-HCN2 channels. We examined
if/how SUMOylation affected Ih using whole cell patch clamp
recordings on Hek-HCN2 cell lines that were transiently
transfected with mCherry, mCherry + SUMO + Ubc9 or
mCherry+ SENP1. Transfected cells were identified by mCherry
fluorescence. Ih was elicited by stepping the voltage from
−50 to −120 mV in 10 mV increments (Figure 5A). The
data showed the treatment that produced a ∼50% increase
in HCN2 SUMOylation (SUMO + Ubc9, Figure 4B) also
produced a mean 77 ± 18.8% increase in Ih Gmax relative
to control (Figure 5B). Overexpression of SENP1 produced
a detectable but not significant mean 31.7 ± 14% decrease
relative to control (Figure 5B), which was consistent with
the finding that SENP1 did not significantly alter baseline
SUMOylation of HCN2 channels. The change in Ih Gmax was
not accompanied by any change in the voltage-dependence
of activation (Figure 5C). Neither the mean V50, nor the
mean slope of the activation curve were significantly different
between control, SUMO + Ubc9, or SENP1 treatment groups
(Figure 5C). Similarly, the time constant for activation was not
significantly different between treatment groups (Figure 5A).
In sum, increased SUMOylation of GFP-HCN2 produced a
corresponding increase in Ih Gmax with no change in voltage
dependence or kinetics of activation.
SUMOylation Increases HCN2 Channel
Surface Expression
We next tested whether or not the SUMOylation-dependent
increase in Ih Gmax was accompanied by an increase in GFP-
HCN2 channel surface expression. A biotinylation assay was
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FIGURE 5 | Increased HCN2 channel SUMOylation augments Ih Gmax. Ih was measured in Hek-HCN2 cells transiently transfected with either mCherry
(control), mCherry + SUMO + Ubc9, or mCherry + SENP1. For each treatment group, data were pooled from ≥3 transfections. (A) Representative traces for each
treatment group, elicited by stepping the voltage from −50 to −120 mV in 10 mV increments. Scale bars, 500 ms and 200 pA. The kinetics of activation at −120 mV
were not altered across treatment groups. Mean activation time constants: control, 400.9 ± 23.01; SUMO + Ubc9, 407.3 ± 33.67; SENP1, 497.4 ± 50.79; one-way
ANOVA, F (2,32) = 2.224; p = 0.1246. (B) Plots of Ih Gmax for each treatment group. Each data point represents a single cell. Bar represents the mean. Transfection
with SUMO + Ubc9 significantly increased Ih Gmax relative to SENP1 and control treatment groups [asterisks, p < 0.05; One-way ANOVA with Tukey’s post hoc,
F (2,28) = 13.23; p < 0.0001]. (C) Plots of voltage dependence of activation. Each data point represents the mean ± SEM. There were no significant differences
between treatment groups for mean V50 [control, −93.88 ± 1.12; SUMO + Ubc9, −91.6 ± 1.29; SENP1, −87.8 ± 3.03; one-way ANOVA, F (2,32) = 3.006;
p = 0.0636] or mean slope [control, −6.61 ± 0.29; SUMO + Ubc9, −7.42 ± 0.41; SENP1, −6.84 ± 0.4; one-way ANOVA, F (2,32) = 1.439; p = 0.252].
used on Hek-HCN2 cells that were transiently transfected
with mCherry or mCherry + SUMO + Ubc9. After 2 days,
transfected cells were incubated with biotin, which binds to cell
surface proteins. The cells were then lysed, and the biotinylated
proteins were pulled out using Neutravidin. The unbiotinylated
(intracellular) and biotinylated (extracellular surface) proteins
were run on an SDS-PAGE gel and transferred to a WB, which
was subsequently divided at ∼50 kDa. The portion of the blot
containing proteins <50 kDa was probed with an antibody
against actin. The ∼37 kDa band corresponding to actin was
only seen in the intracellular fractions, indicating there were
no intracellular proteins contaminating the extracellular surface
samples (Figure 6A). The section of the blot corresponding to
proteins >50 kDa was dually probed with an anti-GFP antibody
and an antibody against the Na+/K+-ATPase (Figure 6A). The
doublet was detected with the anti-GFP antibody. The band
at ∼120 kDa represents the Na+/K+-ATPase. The OD of the
GFP signal (entire GFP-HCN2 doublet) was normalized by
that for the Na+/K+-ATPase signal. We observed a significant
mean 70.6 ± 18.2% increase in HCN2 surface expression
in cells transfected with SUMO + Ubc9 relative to control
(Figure 6B). Based on these findings, we concluded that
the ∼77% increase in Ih Gmax observed upon enhanced
GFP-HCN2 channel SUMOylation was due, at least in part, to
a ∼70% increase in the surface expression of the GFP-HCN2
channel.
Only One of Six Putative SUMOylation
Sites Is Necessary for the Increase in
GFP-HCN2 Surface Expression and Ih
Gmax Elicited by Overexpression of
SUMO and Ubc9
GFP-HCN2 channels can be SUMOylated in our culture system,
and increased SUMOylation leads to an augmentation of Ih
Gmax due, at least in part, to enhanced GFP-HCN2 channel
surface expression. Approximately 63% of all SUMOylation
occurs within a SUMOylation consensus sequence (Hendriks
et al., 2015), e.g., 9KXD/E, with 9 being a hydrophobic residue
and X being any amino acid (Rodriguez et al., 2001; Sampson
et al., 2001; Flotho and Melchior, 2013). We next investigated
if HCN channels possessed SUMOylation consensus sequences.
SUMOplot freeware1 was used to identify potential HCN
SUMOylation sites for all mouse HCN channel isoforms and
for the spiny lobster HCN channel. The amino acid sequences
for all five channels were aligned, SUMOylation consensus
1www.abgent.com/sumoplot
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FIGURE 6 | Increased SUMOylation augments HCN2 channel surface
expression. GFP-HCN2 channel cell surface expression was monitored
using a biotinylation assay. Hek-HCN2 cells were transiently transfected with
mCherry alone or mCherry + SUMO + Ubc9. Two days after transfection
cultures were biotinylated and cell surface proteins were isolated from cell
lysates using Neutravidin. Both the intracellular and cell surface fractions were
run on a WB and probed with antibodies recognizing GFP, Na+/K+-ATPase,
and Actin. (A) Representative WBs. (B) Plots depicting average normalized
GFP-HCN2 channel surface expression (GFP doublet OD ÷ Na+/K+-ATPase
OD). The treatment and the n are shown below the graph. Each n represents
a single plate that was transfected, biotinylated and carried through the
experiment to produce a single lane on a WB. Asterisk indicates significant
difference between treatment groups (Student’s t-test, p < 0.05).
sequences were highlighted for all isoforms and the probability
of SUMOylation, as calculated by SUMOplot, was indicated
(Figure 7). There were six putative HCN2 SUMOylation sites
with probabilities ranging from 32 to 93%. One site was
extracellular (K210) and was not considered further. Two of
the five intracellular HCN2 consensus sequences (K464 and
K484) were observed in all mammalian HCN channel isoforms
and in the lobster HCN channel. The other three consensus
sequences were isoform/species specific. The consensus sequence
containing K669 was exclusive to mouse HCN1 and HCN2
channels. The consensus sequence that included K534 was found
only in mouse HCN2 and lobster HCN channels. The consensus
sequence containing K75 was unique to the mouse HCN2
channel. Additional putative SUMOylation sites not observed in
mouse HCN2 channels existed in other mouse and lobster HCN
channel isoforms.
We next investigated if HCN2 consensus sequences were
substrates for SUMOylation in our culture system. Because
K534 and K669 showed a greater than 90% probability of
SUMOylation (Figure 7), we chose to examine these first. These
two sites were mutated individually and together by changing
the positively charged K residue to a positively charged arginine
(R), which should prevent SUMO conjugation without disrupting
charge interactions (Feliciangeli et al., 2007). Three Hek cell
lines stably expressing the mutated channels were generated:
Hek-HCN2 K534R + K669R, Hek-HCN2 K534R, and Hek-
HCN2 K669R. Each stable mutant cell line was transiently
transfected with mCherry or mCherry + SUMO + Ubc9.
After ∼48 h the fraction of SUMOylated GFP-HCN2 channels
was measured as previously described for Figure 4. Based on
our semi-quantitative measures, the mutations did not appear
to alter baseline HCN2-GFP SUMOylation in the mCherry
treatment group (mean ± SEM; wild-type = 0.31 ± 0.025,
K534R + K669R = 0.41 ± 0.04, K534R = 0.31 ± 0.02, and
K669R = 0.37 ± 0.015; One-way ANOVA F(3,19) = 2.644,
p = 0.0788). On the other hand, the mutations did disrupt
the increase in HCN2-GFP SUMOylation normally elicited
by SUMO + Ubc9 overexpression (Figure 8). Increased
SUMOylation was no longer observed in the Hek-HCN2
K534R + K669R cell line (Figure 8A) or the Hek-HCN2 K669R
cell line (Figure 8C); however, the Hek-HCN2 K534R cell line
still displayed increased SUMOylation upon SUMO + Ubc9
overexpression (Figure 8B). In sum, the data suggest that
overexpression of SUMO + Ubc9 increases SUMOylation at
K669; furthermore, because SUMOylation is still observed when
this site is mutated, at least one additional site on the GFP-HCN2
channel must be SUMOylated.
We next examined Ih Gmax in the mutant cell lines.
Consistent with the previous finding, we observed that
mutating K669 but not K534 prevented the increase in Ih
Gmax upon SUMO + Ubc9 overexpression. Ih Gmax was
not significantly different between the SUMO + Ubc9 vs.
control treatment groups in Hek-HCN2 K534R + K669R
(Figure 9A) or Hek-HCN2 K669R cell lines (Figure 9C).
However, in Hek-HCN2 K534R cells, a 58.2 ± 16.1% increase
in Ih Gmax was still observed in the SUMO + Ubc9
treatment group relative to control (Figure 9B). Together
these data suggest that SUMOylation of K669 is responsible
for the increase in Ih Gmax observed upon overexpression of
SUMO+Ubc9.
Lastly, we tested if mutating K669 prevented the
increase in GFP-HCN2 surface expression normally elicited
by overexpression of SUMO and Ubc9. Hek-HCN2
K669R cells were transiently transfected with mCherry or
mCherry + SUMO + Ubc9 and the biotinylation assay was
performed as described for Figure 6. The data indicated
then when K669 was mutated, overexpression of SUMO and
Ubc9 could no longer elicit an increase in GFP-HCN2 surface
expression (Figure 10). In sum, the K669R mutation blocked
the increase in SUMOylation, Ih Gmax and surface expression
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FIGURE 7 | Identification of HCN2 channels SUMOylation sites. Amino acid sequences for the vertebrate and invertebrate HCN channels were aligned: mouse
HCN1 (NP_034538), mouse HCN2 (NP_032252), mouse HCN3 (NP_032253), mouse HCN4 (NP_001074661), spiny lobster HCN (ABI94038). Putative
SUMOylation sites predicted by SUMOplot freeware are indicated in blue (not mutated this study) or red (mutated in this study). The six transmembrane domains
(yellow) and CNBD (blue) have been highlighted.
normally elicited by overexpression of SUMO + Ubc9. This
suggests that enhanced SUMOylation at K669 augments
GFP-HCN2 surface expression which in turn amplifies Ih Gmax.
DISCUSSION
Ion channels are emerging as targets of SUMOylation. The
extent to which different classes of ion channels are SUMOylated
and the function and regulation of ion channel SUMOylation
are only beginning to be investigated. Here we report, for
the first time, that HCN channels are SUMOylated in vivo
and in a heterologous expression system. IP experiments
with mouse forebrain membrane preparations followed by
Western blotting showed that mouse HCN2 channels were
post-translationally modified by SUMO1, as well as SUMO2
and/or SUMO3 in vivo. HCN2 channels were also SUMOylated
under baseline conditions in a Hek cell line stably expressing
a GFP-HCN2 construct, and transient transfection with SUMO
and the SUMO-conjugating enzyme, Ubc9, increased GFP-
HCN2 channel SUMOylation above baseline. This, in turn,
augmented GFP-HCN2 channel surface expression and produced
a corresponding increase in Ih Gmax without altering the
voltage dependence or kinetics of activation. Using site-directed
mutagenesis of HCN2 and Hek cell lines stably expressing
mutant GFP-HCN2 channels, we showed that SUMOylation
at amino acid K669 was increased upon overexpression of
SUMO + Ubc9, and this alone was responsible for enhanced
GFP-HCN2 channel surface expression and augmentation of
Ih Gmax. However, the K669R mutation, which prevented
SUMOylation at this site, did not alter baseline SUMOylation
of HCN2 channels, suggesting an additional site(s) on the
GFP-HCN2 channel may be SUMOylated under baseline
conditions.
Ion Channels Are SUMOylated In vivo
The effect of SUMO modification on ion channels has become
an area of increasing interest. Previous studies have identified
additional ion channel targets of SUMOylation, and the effect
of SUMOylation on these channels is quite diverse. For
example, SUMO modification of Kv2.1 inhibits the current by
speeding time-dependent inactivation and slowing recovery from
inactivation in pancreatic cells (Dai et al., 2009). However,
SUMOylation of the same channel in hippocampal neurons
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FIGURE 8 | Overexpression of SUMO and Ubc9 enhances SUMOylation at K669. The three mutant cell lines (A–C) were transiently transfected with mCherry
or mCherry + SUMO + Ubc9. Cell lysates were used in IP experiments with anti-GFP antibodies. WBs containing IP products were probed with the anti-SUMO2/3
antibody, stripped and reprobed with the anti-GFP antibody. Top Panel: Representative blots showing the GFP-HCN2 doublet that was measured. Bottom Panel:
Plots of the fraction of SUMOylated GFP-HCN2 channels in each mutant cell line, mean + SEM. The treatment and the n are shown below the graph. Each n
represents one plate that was transfected and carried through the experiment to produce a single lane on a WB. Asterisk significantly different (Student’s t-test,
p < 0.05).
results in a depolarized shift in the voltage dependence of
activation, making the neurons more excitable (Plant et al., 2011).
Studies looking at SUMOylation of the Kv1.5 channel found that
it produced a shift in the voltage dependence of inactivation
(Benson et al., 2007). A recent study showed that in SENP2
null mice hyperSUMOylation of Kv7 channels diminished the
M-current and resulted in neuronal hyperexcitability, leading
to seizures and sudden death (Qi et al., 2014). In addition to
altering the biophysical properties of ion channels, SUMOylation
can alter their surface expression. For example, kainite receptor
SUMOylation leads to internalization of the receptor, and
this effect can be enhanced by agonist binding and PKC
phosphorylation (Martin et al., 2007; Konopacki et al., 2011;
Chamberlain et al., 2012). Here, we have shown that HCN2
channel SUMOylation at K669 increases surface expression and
Ih Gmax. It is important to note that the change in surface
expression may not be the sole explanation for the change in Ih
Gmax; though it was not examined here, changes in biophysical
properties, such as an increase in the open probability (Po) of
the channel, could also contribute to the observed increase in
Ih Gmax. In addition, silent channels in the membrane could be
activated by enhancing protein–protein interactions.
HCN Channels Contain Multiple
SUMOylation Consensus Sequences
The conjugating enzyme, Ubc9, adds SUMO to target proteins.
In some cases, Ubc9 is directed to a SUMOylation site
by an external factor, such as a SIM domain or an E3
ligase. In these instances, SUMOylation does not necessarily
occur at a known consensus sequence (Flotho and Melchior,
2013). In other cases Ubc9 itself recognizes a consensus
sequence and adds SUMO to the K in the consensus
sequence. One study indicates that SUMOylation at known
consensus sequences accounts for ∼63% of all SUMOylation,
although this may vary with the condition, e.g., normal
growth conditions vs. heat shock (Hendriks et al., 2015).
There are five predicted intracellular SUMOylation consensus
sequences in HCN2 (Figure 7). Using Hek cell lines stably
expressing wild type and mutant GFP-HCN2 channels, we
clearly demonstrated that overexpression of SUMO and Ubc9
increased SUMOylation at only one of the five sites, K669.
However, when K669 was mutated, GFP-HCN2 channel
SUMOylation was still observed, suggesting additional sites
were SUMOylated under baseline conditions. Since additional
consensus sequences exist on both the GFP tag and the HCN2
channel, either or both could contribute to the observed
baseline SUMOylation. It is not clear why SUMOylation
did not increase at these site(s) upon overexpression of
SUMO and Ubc9. They may be maximally SUMOylated
and/or additional proteins or regulatory mechanisms may be
necessary for SUMOylation to occur. Alternatively, baseline
SUMOylation may not occur at consensus sequences, in
which case increasing SUMO and Ubc9 should have no
effect.
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FIGURE 9 | Enhanced SUMOylation at K669 augments Ih Gmax. Ih Gmax was measured following transient transfection with mCherry or
mCherry + SUMO + Ubc9 in the three mutant cell lines (A–C). Top panel: Representative traces for each treatment group for each mutant cell line. Scale bars,
500 ms, and 500 pA, Bottom Panel: Plots of normalized Ih Gmax (Gmax ÷ mean mCherry Gmax ) for each mutant cell line. Ih Gmax was normalized to account for
differences in overall expression of the HCN2 channels between the different mutant cell lines, most likely due to difference in the copy number of the plasmid
integrated into the genome. Each data point represents a single cell. Asterisk significantly different (Student’s t-test p < 0.05, recordings were pooled from ≥3
separate transfections).
The five putative HCN2 consensus sequences ranged from
being unique to HCN2 channels to being conserved across
all mouse HCN and lobster channel isoforms. The consensus
sequence that is known to be SUMOylated and which contains
K669 is present exclusively in mouse HCN1 and HCN2 channels.
Our data indicated that SUMOylation at K669 was not necessary
to produce a functional current: Ih was not observed in whole
cell patch clamp recordings from parental Hek cells, but it was
recorded in Hek cells stably expressing GFP-HCN2 channels
with a K669R mutation that prevented SUMOylation at this
site. Although K669 SUMOylation was not necessary, increased
SUMOylation at K669 augmented GFP-HCN2 channel surface
expression and Ih Gmax. These data suggest that SUMOylation
at K669 may alter the rates of channel trafficking to and/or
from the plasma membrane and/or alter channel retention
in the plasma membrane. The surface expression of HCN1
channels can be rapidly adjusted in response to changes in
activity, including seizures (Shah et al., 2004; Noam et al., 2010;
Jung et al., 2011). Activity can also regulate the SUMOylation
of target proteins and the expression and localization of
SUMO and the SUMOylation machinery in neurons (Jaafari
et al., 2013; Loriol et al., 2013; Sun et al., 2014). Thus, it
is possible that changes in activity might alter HCN channel
surface expression by altering SUMOylation at this conserved
site.
The putative HCN2 channel SUMOylation sites at K464 and
K484 were observed in all mouse HCN channel isoforms and
even in the lobster HCN channel (Figure 7), suggesting that they
may play important functional roles. Both K464 and K484 are
in the C-linker that connects the CNBD to the transmembrane
region. The C-linker is necessary for channel trafficking and
cAMP gating (Ulens and Siegelbaum, 2003; Zagotta et al., 2003;
Zhou et al., 2004). The C-linker contains seven α-helices, A–
F (Zagotta et al., 2003); K464 lies between α-helices A and B
while K484 lies between α-helices B and C. Since SUMOylation
is thought to occur only in regions lacking secondary structure,
it is noteworthy that both putative SUMOylation sites lie just
outside of the α-helices. The A and B α-helices in one subunit are
thought to interact with the C and D α-helices in a neighboring
subunit (Zagotta et al., 2003). We have not yet tested whether
these two SUMOylation sites are involved in channel folding,
assembly and/or trafficking, but it may be that SUMOylation
plays a fundamental role in these processes for all HCN channels.
The K534 SUMOylation consensus site lies within the CNBD,
which is also necessary for trafficking and cAMP gating (Akhavan
et al., 2005). According to a previous crystallography study
of the solubilized C-terminus (Zagotta et al., 2003), this site
lies within α-helix A of the CNBD. The K534R mutation did
not appear to alter baseline SUMOylation in our studies, nor
did it prevent the increase in HCN2 SUMOylation observed
upon overexpression of SUMO + Ubc9. Together these data
suggest that K534 may not be SUMOylated in the mature
channel. However, this site was assigned a high score by
SUMOplot, and it is conserved across species, which often
suggests functionality. Since SUMOylation is a dynamic and
highly regulated process (Watts, 2013), it may be that this site
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FIGURE 10 | Enhanced SUMOylation at K669 increases GFP-HCN2
channel surface expression. The K669R mutant cell line was transiently
transfected with mCherry or mCherry + SUMO + Ubc9, followed by the
biotinylation assay to measure GFP-HCN2 surface expression. (A)
Representative blots probed with anti-GFP, anti-Na/K ATPase, and anti-actin
antibodies. (B) Plots of normalized GFP-HCN2 channels in each treatment
group. The treatment and the n are shown below the graph. Each n
represents a single plate that was transfected, biotinylated, and carried
through the experiment to produce a single lane on a WB. There was no
significant difference between treatment groups (Student’s t-test, p = 0.5606).
is transiently SUMOylated in response to a specific signal not
mimicked in our experiments.
Potential SUMO-Dependent HCN2
Channel Interactions
SUMOylation can produce several distinct physiological
consequences, but its primary function is to facilitate
protein–protein interactions through the binding of a SUMO
post-translational modification on the target protein to a SIM
on the interacting partner protein (Hickey et al., 2012). Other
interaction motifs also exist (Flotho and Melchior, 2013).
We have demonstrated that HCN2 channel SUMOylation
can regulate surface expression, and that (putative) HCN2
SUMOylation sites are located in domains that are important for
channel trafficking and surface expression (Proenza et al., 2002;
Tran et al., 2002; Akhavan et al., 2005; Nazzari et al., 2008). Thus,
while SIM containing interaction partners for HCN2 channels
have not yet been identified, it seems likely that they may include
trafficking and scaffold proteins. HCN2 synthesis and assembly
begin in the ER where heavily glycosylated subunits associate
through N- and C-terminal domains (Proenza et al., 2002; Tran
et al., 2002). Channels transit from the ER, through the Golgi
and to the plasma membrane via their interactions with a host
of proteins that mediate vesicular trafficking. Plasma membrane
HCN2 channels can be recycled. Recycled HCN channels are
stored in the endosome recycling compartments below the
plasma membrane until a signal, such as Phospholipase D
activation, triggers insertion back into the plasma membrane
(Hardel et al., 2008). SUMOylation could be involved at any
of these trafficking stages. Scaffold and trafficking proteins are
known to interact with three distinct domains in the C-terminus
of the HCN2 channel: the C-linker, the CNBD, and the ∼230
amino acids distal to the CNBD (Kimura et al., 2004; Santoro
et al., 2004; Lewis et al., 2009; Han et al., 2011). S-SCAM, mint,
and talamin are scaffold and trafficking proteins that form an
assemblage with HCN2 channels through unknown interactions
involving the distal ∼230 amino acids. SUMOylation site K669
is located in this distal fragment, suggesting that SUMOylation
at this site may enhance surface expression by promoting
these assemblages (Han et al., 2011). SUMOylation in the
C-linker and/or the distal fragment could also potentially
promote or prevent the binding of trafficking/scaffolding
proteins like TRIP8b (Santoro et al., 2004; Lewis et al., 2009;
Han et al., 2011) and S-SCAM (Kimura et al., 2004) to the
CNBD.
HCN Channel SUMOylation and
Neurological Disorders
Multiple neurological disease states may be linked to aberrant
SUMOylation. Normally SUMOylation of α-synuclein
promotes a functional, soluble conformation of the protein,
but deSUMOylation leads to α-synuclein aggregation and
cytotoxicity, which are hallmarks of Parkinson’s disease
(Eckermann, 2013). Also, the parkin gene is frequently mutated
in autosomal recessive Parkinson’s patients (Guerra de Souza
et al., 2016). Parkin is a ubiquitin ligase that mediates the
degradation of misfolded mitochondrial proteins. SUMOylation
regulates parkin shuttling from the cytosol to the nucleus,
thereby controlling its availability at the mitochondria (Um
and Chung, 2006). Alzheimer’s disease is characterized by
the formation of neurofibrillary tangles and amyloid-beta
(Aβ)-containing plaques. Two proteins closely associated
with these features, amyloid precursor protein (APP) and
tau, have recently been identified as targets of SUMOylation
(Hoppe et al., 2015). Their improper SUMOylation could
contribute to misfolding and aggregation (Flotho and
Melchior, 2013). Altering the expression of enzymes in the
SUMOylation pathway can lead to seizures due, at least in
part, to hyperSUMOylation of Kv7 channels (Qi et al., 2014).
If SUMOylation is globally disrupted in a given disease, then
multiple targets could be affected, including HCN2 channels.
Indeed, HCN2 channel activity is progressively reduced in
Frontiers in Molecular Neuroscience | www.frontiersin.org 14 January 2017 | Volume 9 | Article 168
fnmol-09-00168 January 11, 2017 Time: 17:42 # 15
Parker et al. SUMOylation Increases HCN2 Surface Expression
a mouse model of Parkinson’s disease leading to altered
pacemaking in globus pallidus neurons (Chan et al., 2011),
and altered HCN2 channel expression has been associated with
seizures in a variety of instances (Ludwig et al., 2003; DiFrancesco
et al., 2011; Nakamura et al., 2013; DiFrancesco and DiFrancesco,
2015). Future studies on the function and regulation of HCN
channel SUMOylation could provide important insights into
HCN2 channel dysfunction in these disease states.
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